Vol. 18/No. 17

Ipatasertib is being investigated in patients with metastatic castration-resistant prostate cancer as a method of simultaneously blocking a resistance mechanism to hormone therapy and improving responses to abiraterone.

During the past decade, the treatment of multiple myeloma has significantly changed, enabling more patients to achieve deep and durable responses.

Although drugs that target HER2 have transformed the prognosis for many patients with breast cancer, the development of resistant disease remains a significant clinical challenge.

After a decade of little movement in the treatment of advanced hepatocellular carcinoma (HCC), there are promising developments on the horizon, according to recent study findings.

John Mendelsohn, MD, served as president of The University of Texas MD Anderson Cancer Center for a 15-year period that saw that institution’s size triple and its budget quadruple.

Supported by research, there have been recent developments in using scalp cooling to combat chemotherapy-induced alopecia for patients with breast cancer.

The decades-long argument over whether zinc lozenges can shorten the duration of the common cold is far removed from the arena of cancer medicine, yet the studies conducted to settle the debate help illustrate the shortcomings of the clinical trial model that has dominated the oncology sphere.